
Results
18
Companies which are more than 50% undervalued based on analyst price target.
18 companies
Nanobiotix
Market Cap: €1.8b
Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
NANO
€34.78
7D
0.06%
1Y
601.2%
Inventiva
Market Cap: €915.6m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.88
7D
0.1%
1Y
40.4%
DBV Technologies
Market Cap: €726.2m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.45
7D
-11.2%
1Y
48.0%
Valneva
Market Cap: €406.2m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.14
7D
-1.6%
1Y
-28.8%
Transgene
Market Cap: €199.1m
A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
TNG
€0.73
7D
-1.8%
1Y
-14.5%
Cellectis
Market Cap: €181.5m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.50
7D
2.7%
1Y
27.6%
Innate Pharma
Market Cap: €146.6m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.56
7D
-0.9%
1Y
-8.1%
Sensorion
Market Cap: €133.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
-3.7%
1Y
-20.2%
OSE Immunotherapeutics
Market Cap: €74.9m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.18
7D
-4.1%
1Y
-43.4%
Adocia
Market Cap: €74.2m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.79
7D
-3.3%
1Y
-23.5%
ABIONYX Pharma
Market Cap: €67.8m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.92
7D
3.2%
1Y
48.1%
THX Pharma Société Anonyme
Market Cap: €53.1m
A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.
ALTHX
€3.85
7D
-0.6%
1Y
222.2%
MaaT Pharma
Market Cap: €51.4m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.73
7D
-1.1%
1Y
-38.2%
AB Science
Market Cap: €44.6m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.56
7D
-13.5%
1Y
-55.1%
Nicox
Market Cap: €33.2m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.38
7D
-1.3%
1Y
15.5%
Advicenne
Market Cap: €23.2m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.59
7D
-8.5%
1Y
34.9%
GenSight Biologics
Market Cap: €19.0m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.081
7D
1.2%
1Y
-39.8%
Valbiotis
Market Cap: €18.8m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.79
7D
1.7%
1Y
-8.2%